BFC Planning, Inc.’s Silexion Therapeutics SLXN Stock Holding History

BFC Planning, Inc.’s Portfolio SLXN Stock Details SLXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$339	Buy	+133	New	+$803	﹤0.01%	3287

Other funds holding SLXN

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Montag & Associates Atlanta, Georgia $2.33B AUM 20.88% 1-Year Est. Return

Pflug Koory Omaha, Nebraska $243M AUM 30.88% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

BFC Planning, Inc.'s SLXN Position: Q2 2026 in Review

BFC Planning, Inc. opened a new position in Silexion Therapeutics (SLXN) in Q2 2026: 133 shares worth $339. The stake represents ﹤0.01% of the portfolio and ranks #3287 among its holdings.

7 funds tracked by Wall St. Rank hold SLXN as of Q2 2026.

BFC Planning, Inc. held 133 shares of Silexion Therapeutics worth $339 as of Q2 2026.
Silexion Therapeutics was a new BFC Planning, Inc. position in Q2 2026.
Silexion Therapeutics made up ﹤0.01% of BFC Planning, Inc.'s portfolio in Q2 2026, its #3287 holding.
7 funds tracked by Wall St. Rank held Silexion Therapeutics as of Q2 2026.

Based on BFC Planning, Inc.'s 13F filing for Q2 2026, filed 29 Oct 2026.